Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial
CONFIRMED85% CONFIDENCEThe release is datelined "TITUSVILLE, N.J. (September 21, 2026) - Johnson & Johnson (NYSE: JNJ[1][4]) today announced positive topline results from the pivotal Phase 3 study", and its PR Newswire copy is timestamped "Sep 21, 2026, 08:00 ET" (12:00 UTC).
Johnson & Johnson reported positive topline results from Study 451: once-daily Caplyta (lumateperone) 42 mg cut manic symptoms in bipolar I disorder by 4.8 YMRS points more than placebo at week 3, with a significant effect from day 3.
1.00